Mark For: LEBFYSA™ trademark registration is intended to cover the categories of pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Corona virus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases; Diagnostic agents, preparations and substances for medical purposes; diagnostic scanning agents for medical use, namely, diagnostic scanning agents for in vivo use; radiopharmaceutical diagnostic preparations for medical use; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative amyloid diseases. [all]
Status
2021-07-25 UTC
LIVE APPLICATION Published for Opposition
A pending trademark application has been examined by the Office and has been published in a way that provides an opportunity for the public to oppose its registration.
(Pharmaceuticals) Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
Filed Use
No
Current Use
No
Intent To Use
Yes
Filed ITU
Yes
44D Filed
No
44E Current
No
66A Current
No
Current Basis
No
No Basis
No
Attorney Name
Bruce W. Longbottom
Timeline
2020-11-02
Application Filed
2020-11-05
Location: NEW APPLICATION PROCESSING
2020-11-05
Status: Live/Pending
2020-11-06
Transaction Date
2021-05-11
Published
2021-07-06
Location: INTENT TO USE SECTION
2021-07-06
Status: Notice of Allowance (NOA) sent (issued) to the applicant. Applicant must file a Statement of Use or Extension Request within six
BRUCE W. LONGBOTTOM ELI LILLY AND COMPANY LILLY CORPORATE CENTER INDIANAPOLIS, IN 46285
Good, Services, and Codes
IC 005. US 005 006 018 044 046 051 052. G & S: Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Corona virus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases; Diagnostic agents, preparations and substances for medical purposes; diagnostic scanning agents for medical use, namely, diagnostic scanning agents for in vivo use; radiopharmaceutical diagnostic preparations for medical use; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative amyloid diseases
International Codes:
5
U.S. Codes:
005,006,018,044,046,051,052
Type Code
Type
GS0051
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases; Diagnostic agents, preparations and substances for medical purposes; diagnostic scanning agents for medical use, namely, diagnostic scanning agents for in vivo use; radiopharmaceutical diagnostic preparations for medical use; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative amyloid diseases
Trademark Filing History
Description
Date
Proceeding Number
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
2021-07-06
PUBLISHED FOR OPPOSITION
2021-05-11
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
2021-05-11
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
2021-04-21
ASSIGNED TO EXAMINER
2021-04-06
76509
APPROVED FOR PUB - PRINCIPAL REGISTER
2021-04-06
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.